Clinical Trial

A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 11, 2022 (before its estimated January 15, 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-12-21.
Status change: Not Yet Recruiting → Recruiting 2022-05-06
Trial Details
NCT Number NCT05182944
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions Esophageal Cancer
Enrollment 130 participants
Start Date 2022-01-15
Primary Completion 2024-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2022-05-11